Metformin vs Rapamycin in Aging Research

Compares what mouse studies, human observational data, early human trials and prescribing labels show for metformin and rapamycin in aging research, without use guidance.

Content last updated October 22, 2026. This page has not been medically reviewed.

Two prescription medicines, one research question

Metformin and rapamycin (also called sirolimus) are prescription medicines that researchers study for their effects on aging biology. This page compares the evidence only. It gives no guidance on use. Neither is approved to treat aging, and anyone taking either for another reason should talk with their prescriber before changing anything.

Evidence labels used: approved medicine (for the label's own indication), preclinical (cells/animals only), promising but limited, mixed, and insufficient evidence. A lifespan result in mice is not a result in people, and a lab or biomarker change is not a health outcome.

What the labels say

The U.S. prescribing label for metformin tablets lists its indication as an adjunct to diet and exercise to improve blood sugar control in adults and children with type 2 diabetes.[1] It carries a warning about lactic acidosis, described as rare but serious.[1] The sirolimus tablet label lists prevention of organ rejection in kidney transplant patients aged 13 and over, and warns that immunosuppression may increase susceptibility to infection and possibly lymphoma and other malignancies.[2] The sections of the labels read here do not list aging as an indication for either medicine.

Side-by-side evidence

Question	Metformin	Rapamycin
Mouse lifespan	In a multi-site mouse program, metformin alone at the tested diet level did not significantly extend lifespan.[3] A separate study reported longer life in male mice at a lower dose, with a higher dose toxic.[4]	Extended median and maximal lifespan in both male and female mice when started late in life.[5]
Human observational data	People with type 2 diabetes starting metformin had longer adjusted survival than matched people without diabetes in one UK database study.[6]	None read for this page: proper evidence not found in the sources checked.
Human trials in older adults	MASTERS (94 healthy adults 65 and over) found less muscle gain with metformin than placebo during resistance training.[7] A second trial found less fitness gain after aerobic training.[8]	PEARL, a 48-week placebo-controlled trial in healthy adults, reported the weekly low-dose regimen relatively safe, with no significant change in visceral fat; the authors said efficacy still needs to be established.[9]
Main safety signals on labels	Lactic acidosis[1]	Immunosuppression and infection risk[2]

How to read the table

Mouse results differ between medicines. The rapamycin lifespan effect was seen at three independent test sites (preclinical).[5] For metformin, results are mixed across studies.[3][4] In the same program, metformin combined with rapamycin extended lifespan, a result judged against earlier rapamycin-alone studies rather than a side-by-side comparison.[3]
The metformin human data are observational. The diabetes comparison is a retrospective database analysis, so people who received metformin may have differed from others in ways the study could not fully measure. It does not show metformin extends life in people without diabetes.[6]
The planned test is a trial, not a result. The metformin trial known as TAME was described in 2016 as the planned test.[10] For current status, see the Research Library guide on aging trials.
Rapamycin human data are early. PEARL's abstract reports improved lean tissue mass and pain in women at one regimen, and some well-being scores at another. The primary outcome was visceral fat, which did not change significantly, and the abstract notes no significant effects beyond those listed (promising but limited).[9] A different 264-person trial used other mTOR-blocking drugs for 6 weeks and reported fewer infections reported by older adults, but those drugs are not rapamycin itself.[11]
Funding and conflicts were not part of the abstracts read here.

No winner

The comparison does not rank one above the other. They are different drug classes with different known risks, tested in different ways, and neither has been shown to extend human lifespan.

Frequently asked questions

Is either medicine approved to treat aging?

The labels read for this page list type 2 diabetes for metformin and kidney transplant rejection prevention for sirolimus, not aging.[1][2]

Did these medicines make mice live longer?

Rapamycin did in a multi-site mouse study.[5] Metformin alone did not significantly in the same program, though another study reported longer life in male mice.[3][4] Mouse results do not show the same effect in people.

What are the main risks listed on the labels?

Metformin: lactic acidosis.[1] Sirolimus: immunosuppression, with higher susceptibility to infection and possible lymphoma and other malignancies.[2]

Can metformin interfere with exercise benefits?

In two trials of older adults, metformin reduced muscle gain after resistance training and fitness gain after aerobic training.[7][8]

Should I ask my doctor for either one for aging?

This page cannot recommend that. Discuss your own situation with a prescriber.

References

Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.